VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the article, VistaGen’s CEO Shawn Singh discussed the company’s ongoing efforts to treat and help manage the anxiety symptoms provoked by COVID-19 and other triggers, anxiety-related disorders initially in subjects suffering from Social Anxiety Disorder (“SAD”), as well as the FDA’s consensus on the design of the company’s pivotal Phase III study of PH94B. The piece quotes Singh, who states, “Now more than ever, patients around the world need new medications that go beyond the standard of care for anxiety, depression and suicidal ideation. For patients who have a debilitating mental health condition, our goal with PH94B for SAD, as well as for several other anxiety disorders, is to develop and offer an innovative, life-changing treatment that goes beyond the current standard of care and allows patients to manage their anxiety to the point where they are able to live their lives as the ideal version of themselves—a crucial driver for everything we do.”
To view the full article, visit https://ibn.fm/Ym21x
About VistaGen Therapeutics
VistaGen is a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other CNS disorders where the current standard of care is inadequate, resulting in high unmet need. Each of VistaGen’s three drug candidates has a differentiated mechanism of action, an exceptional safety profile in all studies to date, and therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment